{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25+IV&page=2",
    "query": {
      "intervention": "Saline 0.9% IV",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 386,
    "total_pages": 39,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25+IV&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25+IV&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T16:33:11.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04435184",
      "title": "Crizanlizumab for Treating COVID-19 Vasculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "DRUG"
        },
        {
          "name": "0.9% saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-07-09",
      "completion_date": "2021-01-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04435184"
    },
    {
      "nct_id": "NCT04603742",
      "title": "Anakinra, COVID-19, Cytokine Storm",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Cytokine Storm",
        "Mechanical Ventilation Complication"
      ],
      "interventions": [
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-12",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-01-25",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04603742"
    },
    {
      "nct_id": "NCT01527942",
      "title": "Intravenous Acetaminophen Use With Bariatric Surgery on Morbidly Obese Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trinity Health Of New England",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "20 Years to 70 Years"
      },
      "enrollment_count": 34,
      "start_date": "2012-03",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2015-12-17",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527942"
    },
    {
      "nct_id": "NCT01264783",
      "title": "Safety and Tolerability of RNS60 Given by IV to Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myocardial Infarct"
      ],
      "interventions": [
        {
          "name": "RNS60",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revalesio Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2011-07",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-10-04",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264783"
    },
    {
      "nct_id": "NCT03533777",
      "title": "Antegrade Versus Retrograde IV for Blood Draws",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "There is no Focus on Any Specific Condition"
      ],
      "interventions": [
        {
          "name": "Peripheral intravenous catheter placement",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood draw",
          "type": "OTHER"
        },
        {
          "name": "Peripheral intravenous catheter",
          "type": "DEVICE"
        },
        {
          "name": "To keep open (TKO) infusion of 0.9% normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 230,
      "start_date": "2018-06-22",
      "completion_date": "2019-06-19",
      "has_results": false,
      "last_update_posted_date": "2019-07-01",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03533777"
    },
    {
      "nct_id": "NCT03133767",
      "title": "Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fluid Loss",
        "Symptom Complex, Triple",
        "Emergencies"
      ],
      "interventions": [
        {
          "name": "Lactated Ringer Solution",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline 0.9% Infusion Solution Bag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicholas M Mohr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2017-05-23",
      "completion_date": "2017-11-02",
      "has_results": true,
      "last_update_posted_date": "2018-09-11",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03133767"
    },
    {
      "nct_id": "NCT04348500",
      "title": "Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2020-04-28",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04348500"
    },
    {
      "nct_id": "NCT01753076",
      "title": "Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 304,
      "start_date": "2012-12-20",
      "completion_date": "2015-01-22",
      "has_results": true,
      "last_update_posted_date": "2017-12-21",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01753076"
    },
    {
      "nct_id": "NCT00589888",
      "title": "FFA-Induced Hypertension and Endothelial Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Endothelial Dysfunction",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Intralipid 20% @ 20cc/hour",
          "type": "DRUG"
        },
        {
          "name": "Intralipid 20%@ 40cc/hour",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        },
        {
          "name": "32-gram oral fat load",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "64-gram oral fat load",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-08",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2018-10-16",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589888"
    },
    {
      "nct_id": "NCT06253923",
      "title": "Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Amantadine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SHINKEI Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2024-06-01",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-10-03T16:33:11.004Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Sacramento, California • Gainesville, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06253923"
    }
  ]
}